Verastem (VSTM) News Today $9.29 +0.72 (+8.40%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$9.12 -0.17 (-1.87%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Verastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average - Here's What Happened1 hour ago | marketbeat.comVerastem's (VSTM) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comVerastem: Navigating Critical Steps In Commercialization And Development (Downgrade)October 7, 2025 | seekingalpha.comVerastem (NASDAQ:VSTM) Shares Up 4.9% - Still a Buy?October 7, 2025 | marketbeat.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Given Average Rating of "Moderate Buy" by BrokeragesOctober 6, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average - Should You Sell?October 4, 2025 | marketbeat.comWall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"September 21, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Trading Up 5.6% - Still a Buy?September 18, 2025 | marketbeat.comVerastem, Inc. $VSTM Shares Acquired by Goldman Sachs Group Inc.September 18, 2025 | marketbeat.comTop Biotech Picks for 2025: BTIG Research Highlights Potential WinnersSeptember 16, 2025 | finance.yahoo.comVerastem (NASDAQ:VSTM) Lowered to Sell Rating by Wall Street ZenSeptember 15, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by AnalystsSeptember 13, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Trading Down 7.6% - Should You Sell?September 12, 2025 | marketbeat.comBTIG Research Reaffirms Buy Rating for Verastem (NASDAQ:VSTM)September 11, 2025 | marketbeat.comOctagon Capital Advisors LP Invests $10.37 Million in Verastem, Inc. $VSTMSeptember 11, 2025 | marketbeat.comPolar Asset Management Partners Inc. Invests $300,000 in Verastem, Inc. $VSTMSeptember 9, 2025 | marketbeat.comLeerink says competitor data suggest promising view for Revolution’s zoldonrasibSeptember 8, 2025 | msn.comVerastem Updates on Cancer Therapy DevelopmentsSeptember 8, 2025 | tipranks.comNuveen LLC Makes New Investment in Verastem, Inc. $VSTMSeptember 8, 2025 | marketbeat.comNomura Holdings Inc. Invests $1.26 Million in Verastem, Inc. $VSTMSeptember 6, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Hits New 1-Year High - Should You Buy?September 5, 2025 | marketbeat.comNantahala Capital Management LLC Sells 1,454,042 Shares of Verastem, Inc. $VSTMSeptember 3, 2025 | marketbeat.comWellington Management Group LLP Takes Position in Verastem, Inc. $VSTMSeptember 2, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Sets New 1-Year High - What's Next?August 30, 2025 | marketbeat.comB. Riley Upgrades Verastem (NASDAQ:VSTM) to Strong-BuyAugust 29, 2025 | marketbeat.comVerastem Oncology to Present at Upcoming Investor ConferencesAugust 27, 2025 | mms.businesswire.comVerastem, Inc. $VSTM Shares Sold by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comVerastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?August 25, 2025 | tipranks.comBalyasny Asset Management L.P. Increases Stake in Verastem IncAugust 20, 2025 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 18, 2025 | marketbeat.comZacks Research Upgrades Verastem (NASDAQ:VSTM) to "Hold"August 17, 2025 | marketbeat.comVerastem Advances with Phase 3 Trial Progress and Product Launch Boosting ProspectsAugust 17, 2025 | insidermonkey.comVerastem Advances with Phase 3 Trial Progress and Product Launch Boosting ProspectsAugust 17, 2025 | finance.yahoo.comVerastem price target lowered to $14 from $16 at MizuhoAugust 15, 2025 | msn.comVerastem stock soars after KRAS inhibitor shows strong lung cancer resultsAugust 14, 2025 | za.investing.comVerastem Unveils Promising VS-7375 Study ResultsAugust 14, 2025 | msn.comVerastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung CancerAugust 13, 2025 | businesswire.comVerastem Inc. Earnings Call: Positive Outlook with Key AchievementsAugust 13, 2025 | msn.comVerastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comVerastem (NASDAQ:VSTM) Releases Quarterly Earnings ResultsAugust 10, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Price Target Raised to $13.00August 10, 2025 | marketbeat.comVerastem, Inc. (VSTM) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comVerastem, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 8, 2025 | seekingalpha.comVerastem climbs on Q2 beat as new ovarian cancer drug boosts toplineAugust 8, 2025 | msn.comRBC Capital Raises Verastem (VSTM) Price Target to $13. ...August 8, 2025 | gurufocus.comVerastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesAugust 8, 2025 | finance.yahoo.comVerastem’s Promising Market Expansion and Financial Health Drive Buy RatingAugust 8, 2025 | tipranks.com Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approvalAugust 8, 2025 | investing.comJefferies Financial Group Inc. Makes New $1.63 Million Investment in Verastem, Inc. (NASDAQ:VSTM)August 4, 2025 | marketbeat.com Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.540.75▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼65▲VSTM Articles Average Week Get the Latest News and Ratings for VSTM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Verastem and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MannKind News Celldex Therapeutics News Novavax News BioCryst Pharmaceuticals News OPKO Health News Dynavax Technologies News Innoviva News Zenas BioPharma News Geron News Myriad Genetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
